Topiroxostat

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Topiroxostat
Topiroxostat.svg
Clinical data
Trade namesTopiloric, Uriadec
ATC code
  • None
Legal status
Legal status
  • Approved in Japan
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H8N6
Molar mass248.24 g/mol g·mol−1
3D model (JSmol)

Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.[1] It was approved for use in Japan in June 2013.[1]

Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.[2]

References[edit]

  1. ^ a b "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22. Cite uses deprecated parameter |deadurl= (help); Cite journal requires |journal= (help)
  2. ^ Hosoya, Tatsuo; Ohno, Iwao; Nomura, Shinsuke; Hisatome, Ichiro; Uchida, Shunya; Fujimori, Shin; Yamamoto, Tetsuya; Hara, Shigeko (2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. doi:10.1007/s10157-014-0935-8. PMC 4271138.